Oncodetect check makes use of circulating tumor DNA to evaluate recurrence danger throughout stable tumors and information therapy choices.
A brand new check designed to detect molecular residual illness (MRD) throughout a number of stable tumors, Oncodetect, was introduced by Precise Sciences Corp., to supply sufferers with most cancers and their healthcare suppliers with the insights wanted to make extra knowledgeable choices all through the therapy course of, based on a information launch from the corporate.
Utilizing entire exome sequencing, the check analyzes circulating tumor DNA shed into the bloodstream, providing perception into adjustments in DNA ranges over time. This quantitative measurement, reported in MTM/mL (imply tumor molecules per milliliter of plasma), helps healthcare suppliers assess a affected person’s illness standing.
“Precise Sciences is reworking most cancers care by delivering assessments that present the readability sufferers and physicians must make assured choices,” Brian Baranick, government vp and normal supervisor of Precision Oncology at Precise Sciences, stated within the information launch. “After surgical procedure and definitive remedy, corresponding to chemotherapy or radiation, the danger for most cancers recurrence stays a significant concern. Superior detection instruments just like the Oncodetect check assist bridge that hole by offering medical insights at vital durations, resulting in extra knowledgeable therapy choices and personalised care.”
The Oncodetect check gives a transparent “Detected” or “Not Detected” outcome together with quantitative knowledge to assist information adjuvant remedy, assess therapy response and monitor most cancers recurrence. Sufferers who check constructive for circulating tumor DNA with the check throughout surveillance are 50 instances extra prone to expertise a recurrence than these with adverse outcomes. The extremely delicate and personalised check tracks as much as 200 tumor-specific variants and may detect a single ctDNA molecule amongst 20,000 cell-free DNA molecules, permitting earlier detection of colorectal most cancers recurrence than imaging alone.
Backed by almost 5 years of knowledge from the Alpha-CORRECT examine, one of many longest-followed MRD cohorts for colorectal most cancers recurrence, the Oncodetect check helps inform recurrence danger and information personalised therapy choices. Precise Sciences is working with Medicare to safe reimbursement and develop entry, whereas additionally advancing validation research throughout a number of stable tumors by strategic partnerships.
“Precise Sciences is a longtime trusted associate in addressing the vital unmet wants in colorectal most cancers care, guaranteeing sufferers have the insights they should navigate therapy with confidence,” Vanessa Ghigliotty, Licensed Affected person Navigator and Chair, Affected person Advisory Board, GI Cancers Alliance, stated within the information launch. “For these dealing with the uncertainty of recurrence, tumor-informed MRD assessments just like the Oncodetect check can present clear, well timed solutions — empowering sufferers to take an lively function of their care and obtain the fitting therapy on the proper time for higher outcomes.”
The Oncodetect check builds on 20 years of genomic testing established by the Oncotype DX Breast Recurrence Rating and is built-in right into a digital platform supported by ExactNexus. It may be ordered with different Precise Sciences assessments, together with OncoExTra for genomic profiling and Riskguard for hereditary most cancers testing. With greater than three million People eligible for MRD testing, Precise Sciences goals to assist advance personalised care, as per the discharge.
The ALPHA-CORRECT Research and Beta-CORRECT Research
On the 2025 American Society of Scientific Oncology (ASCO) Gastrointestinal Cancers (GI) Symposium, outcomes from the Alpha-CORRECT examine confirmed the Oncodetect check reached 78% sensitivity after surgical procedure and 91% throughout surveillance, with specificities of 80% and 94%, respectively.
Moreover, Oncodetect met its major endpoint within the Beta-CORRECT examine, confirming a powerful hyperlink between MRD positivity and recurrence in sufferers with stage 3 colon most cancers. Along with knowledge shared at ASCO GI, the findings assist Oncodetect’s prognostic worth in sufferers with stage 2 and 4 colon most cancers and rectal most cancers.
For extra information on most cancers updates, analysis and schooling, don’t neglect to subscribe to CURE®’s newsletters right here.
